Compare T & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | T | JNJ |
|---|---|---|
| Founded | 1983 | 1886 |
| Country | United States | United States |
| Employees | 133030 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.5B | 542.4B |
| IPO Year | N/A | 2003 |
| Metric | T | JNJ |
|---|---|---|
| Price | $22.82 | $239.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 20 |
| Target Price | $30.55 | ★ $238.20 |
| AVG Volume (30 Days) | ★ 42.5M | 7.4M |
| Earning Date | 04-22-2026 | 04-14-2026 |
| Dividend Yield | ★ 4.31% | 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 2.14 |
| Revenue | N/A | N/A |
| Revenue This Year | $4.34 | $6.63 |
| Revenue Next Year | $2.14 | $7.43 |
| P/E Ratio | ★ $9.14 | $108.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.99 | $150.73 |
| 52 Week High | $29.79 | $251.71 |
| Indicator | T | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 59.01 |
| Support Level | $22.82 | $233.83 |
| Resistance Level | $23.61 | $244.80 |
| Average True Range (ATR) | 0.62 | 4.60 |
| MACD | -0.01 | 0.22 |
| Stochastic Oscillator | 43.31 | 87.09 |
The wireless business contributes nearly 70% of AT&T's revenue. The company is the third-largest US wireless carrier, connecting 74 million postpaid and 17 million prepaid phone customers. Fixed-line enterprise services, which account for about 14% of revenue, include internet access, private networking, security, voice, and wholesale network capacity. Residential services, about 11% of revenue, primarily consist of in-home broadband internet access, serving 15 million customers. AT&T also has a sizable presence in Mexico, with 25 million wireless customers, but this business only accounts for 3% of revenue. The company recently sold its 70% equity stake in satellite television provider DirecTV to its partner, private equity firm TPG.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.